NCT04668339 - A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults | Biotech Hunter

Enrollment

581

Participants

Timeline

Start Date

January 7, 2021

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions

Covid19SARS-CoV InfectionCorona Virus Infection

Interventions

BIOLOGICAL

ARCT-021 single dose priming

ARCT-021 higher dose (one dose) + placebo (one dose)

BIOLOGICAL

ARCT-021 two lower dose priming

ARCT-021 lower dose (two doses, Day 0 and Day 28)

BIOLOGICAL

ARCT-021 two higher dose priming

ARCT-021 higher dose (two doses, Day 0 and Day 28)

BIOLOGICAL

Placebo (two doses), priming

Placebo (two doses, Day 0 and Day 28)

BIOLOGICAL

Randomized booster

ARCT-021 (single dose) OR placebo, booster

BIOLOGICAL

Placebo booster

Placebo (single dose)

Trial Locations (15)

20850

Arcturus Investigational Site 110, Rockville

29621

Arcturus Investigational Site 102, Anderson

32162

Arcturus Investigational Site 109, The Villages

32806

Arcturus Investigational Site 105, Orlando

32934

Arcturus Investigational Site 104, Melbourne

33781

Arcturus Investigational Site 106, Pinellas Park

61614

Arcturus Investigational Site 101, Peoria

75234

Arcturus Investigational Site 108, Dallas

78705

Arcturus Investigational Site 111, Austin

85224

Arcturus Investigational Site 103, Chandler

85741

Arcturus Investigational Site 107, Tucson

92108

Arcturus Investigational Site 112, San Diego

117599

Arcturus Investigational Site 204, Singapore

169608

Arcturus Investigational Site 201, Singapore

308433

Arcturus Investigational Site 203, Singapore